a few things. first of all, it had a slight surprise that it lost a $1.5m ebitda contract skin care contract in FY17. This is not affecting prospectus though. But mkt doesnt like surprises no matter how small.
Second of all - expectation. People saw BKL and jumped on the train expecting similar things in their vitamins. Although growth was solid, it didnt exceed expectations like BKL has done. China sales are very small with VIT. So BKL's success has actually been negative for VIT as too much expectation.
Also, market conditions. They have been weak globally the past 4 months. This has led to smaller fund managers selling down their VIT holdings. BAL another stock in the same sector, is well down from the high point only.
Price wise i dont think it was overvalued, but fair only at IPO price, not huge money on the table as private equity vendor who has more knowledge than the buyer.
Lastly management. They seem to be more the quiet, execution type, but will get job done behind the limelight. They have no intention of promotion of already known info beyond the necessary.
Add to My Watchlist
What is My Watchlist?
